Regional brain kinetics of 6-fluoro-(beta-11C)-L-dopa and (beta-11C)-L-dopa following COMT inhibition. A study in vivo using positron emission tomography
- PMID: 1536715
- DOI: 10.1007/BF01253107
Regional brain kinetics of 6-fluoro-(beta-11C)-L-dopa and (beta-11C)-L-dopa following COMT inhibition. A study in vivo using positron emission tomography
Abstract
The regional brain kinetics of (beta-11C)-L-dopa and 6-fluoro-(beta-11C)-L-dopa was measured in six Rhesus monkeys using positron emission tomography (PET). Radioactivity accumulated specifically in the striatal region and the increase in L-dopa-derived radioactivity utilization with time was calculated using surrounding brain as a reference area, this being devoid of dopaminergic activity. The rate constant for selective striatal utilization i.e. grossly decarboxylation was 0.0110 +/- 0.0007 (S.D) and 0.0057 +/- 0.0006 min-1 for (beta-11C)-L-dopa and 6-fluoro-(beta-11C)-L-dopa, respectively. After pretreatment of the monkeys with the peripherally and centrally active catecholamine-O-methyl transferase (COMT) inhibitor Ro 40-7592 10 mg/kg, the decarboxylation rate remained unchanged (0.0112 +/- 0.0015 min-1) for (beta-11C)-L-dopa, whereas an increase in rate was measured for 6-fluoro-(beta-11C)-L-dopa (0.0092 +/- 0.0015 min-1). Differences in the distribution of radiolabelled metabolites i.e. the corresponding O-methyl-L-dopa in the reference area is most probably the reason for the difference in calculated decarboxylation rate seen between the radiotracers. The higher decarboxylation rate measured for 6-fluoro-(beta-11C)-L-dopa after blockade of COMT shows that the radiolabelled metabolites i.e. 6-fluoro-O-methyl-(beta-11C)-L-dopa significantly contributes to background radioactivity.
Similar articles
-
Positron emission tomography in drug evaluation: influence of three different catechol-O-methyltransferase inhibitors on metabolism of [NCA] 6-[18F]fluoro-L-dopa in rhesus monkey.Nucl Med Biol. 1995 Oct;22(7):921-7. doi: 10.1016/0969-8051(95)00032-s. Nucl Med Biol. 1995. PMID: 8547890
-
A comparison of 11C-labeled L-DOPA and L-fluorodopa as positron emission tomography tracers for the presynaptic dopaminergic system.J Cereb Blood Flow Metab. 1999 Oct;19(10):1142-9. doi: 10.1097/00004647-199910000-00011. J Cereb Blood Flow Metab. 1999. PMID: 10532639
-
Effects of peripheral and central catechol-O-methyltransferase inhibition on striatal extracellular levels of dopamine: a microdialysis study in freely moving rats.Parkinsonism Relat Disord. 2003 Jan;9(3):145-50. doi: 10.1016/s1353-8020(02)00016-0. Parkinsonism Relat Disord. 2003. PMID: 12573869
-
General properties and clinical possibilities of new selective inhibitors of catechol O-methyltransferase.Gen Pharmacol. 1994 Sep;25(5):813-24. doi: 10.1016/0306-3623(94)90082-5. Gen Pharmacol. 1994. PMID: 7835624 Review.
-
Compartmental analysis of dopa decarboxylation in living brain from dynamic positron emission tomograms.Synapse. 1998 May;29(1):37-61. doi: 10.1002/(SICI)1098-2396(199805)29:1<37::AID-SYN4>3.0.CO;2-C. Synapse. 1998. PMID: 9552174 Review.
Cited by
-
Central action of benserazide after COMT inhibition demonstrated in vivo by PET.J Neural Transm Gen Sect. 1991;85(1):11-7. doi: 10.1007/BF01244653. J Neural Transm Gen Sect. 1991. PMID: 1867835
-
Radiosynthesis, Preclinical, and Clinical Positron Emission Tomography Studies of Carbon-11 Labeled Endogenous and Natural Exogenous Compounds.Chem Rev. 2023 Jan 11;123(1):105-229. doi: 10.1021/acs.chemrev.2c00398. Epub 2022 Nov 18. Chem Rev. 2023. PMID: 36399832 Free PMC article. Review.
-
From Carbon-11-Labeled Amino Acids to Peptides in Positron Emission Tomography: the Synthesis and Clinical Application.Mol Imaging Biol. 2018 Aug;20(4):510-532. doi: 10.1007/s11307-018-1163-5. Mol Imaging Biol. 2018. PMID: 29411226 Review.
-
Exploring Metabolism In Vivo Using Endogenous 11C Metabolic Tracers.Semin Nucl Med. 2017 Sep;47(5):461-473. doi: 10.1053/j.semnuclmed.2017.05.003. Epub 2017 Jul 11. Semin Nucl Med. 2017. PMID: 28826521 Free PMC article. Review.
-
Clinical Potential of Catechol-OMethyltransferase (COMT) Inhibitors as Adjuvants in Parkinson's Disease.CNS Drugs. 1994 Mar;1(3):172-9. doi: 10.2165/00023210-199401030-00002. CNS Drugs. 1994. PMID: 27520516
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Research Materials
Miscellaneous